Stockscreener 앱 받기
0.2678
1.40%
-0.0042
전일 마감가:
$0.272
열려 있는:
$0.2657
하루 거래량:
982.78K
Relative Volume:
0.18
시가총액:
$42.77M
수익:
$506.20K
순이익/손실:
$-42.05M
주가수익비율:
-1.0117
EPS:
-0.2647
순현금흐름:
$-31.36M
1주 성능:
-7.64%
1개월 성능:
-13.32%
6개월 성능:
-27.63%
1년 성능:
-84.67%
1일 변동 폭
$0.2616
$0.2736
1주일 범위
$0.2616
$0.294
52주 변동 폭
$0.20
$2.37
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
명칭
Mereo Biopharma Group Plc Adr
전화
4403330237300
주소
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.2678 | 46.84M | 506.20K | -42.05M | -31.36M | -0.2647 |
VRTX
Vertex Pharmaceuticals Inc
|
542.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.37 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.15 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.68 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-12-30 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2023-10-13 | 재개 | BTIG Research | Buy |
| 2022-08-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Needham | Buy |
모두보기
Mereo Biopharma Group Plc Adr 주식(MREO)의 최신 뉴스
Form 8K MEREO BIOPHARMA GROUP PLC For: 19 August By Investing.com - Investing.com Nigeria
Mereo BioPharma (NASDAQ: MREO) given 2027 Nasdaq deadline - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Here's Why We're Not Too Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - Sahm
Mereo BioPharma Group PLC ADR (NASDAQ: MREO) Stock Price, News & Analysis - Kalkine
Mereo BioPharma Q2 Results: Net loss narrows 52% YoY to $7.0 million - scanx.trade
Form 8K MEREO BIOPHARMA GROUP PLC For: 11 August By Investing.com - Investing.com South Africa
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights - GlobeNewswire
Defilade Capital Management L.P. Makes New Investment in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Short Interest Update - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPhar - The National Law Review
MAH0 Forecast — Price Target — Prediction for 2027 - TradingView
MREO News | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
MREOMereo Biopharma Group Plc ADR Stock Price and Quote - Finviz
Mereo BioPharma shareholders approve all resolutions at annual meeting By Investing.com - Investing.com Australia
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - Eastern Progress
Mereo BioPharma shareholders approve all resolutions at annual meeting - Investing.com
Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers - Stock Titan
Mereo BioPharma Reports Q1 2026 Financial Results and Updates on Setrusumab, Alvelestat, and Vantictumab Clinical Progress - Minichart
Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed - Stock Titan
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Mereo BioPharma Reports Q1 2026 Financial Results, Advances Setrusumab and Alvelestat Clinical Programs, and Provides Cash Runway Update - Minichart
[10-Q] Mereo BioPharma Group plc Quarterly Earnings Report - Stock Titan
Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans - Stock Titan
Trials miss fracture goals, but Mereo drug boosts bone density in OI - Stock Titan
MREO Stock Price, Quote & Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
Mereo BioPharma (MREO) 2026 AGM to vote on share issuance, pay and directors - Stock Titan
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - GlobeNewswire Inc.
MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - ChartMill
DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 - ChartMill
Pomerantz LLP Shares Class Action Details With Shareholders in Mereo BioPharma Group plc – MREO - ACCESS Newswire
MREO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - chartmill.com
Pomerantz LLP Notifies Investors of Class Action Filing Against Mereo BioPharma Group plc – MREO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - ChartMill
MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm - Barchart.com
Pomerantz LLP Reminds Shareholders: Securities Lawsuit Has Been Filed Against Mereo BioPharma Group plc – MREO - accessnewswire.com
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast - Defense World
Mereo BioPharma director Annalisa Jenkins to step down after annual meeting By Investing.com - Investing.com South Africa
Mereo Biopharma Group Plc Adr (MREO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.38%
자본화:
|
볼륨(24시간):